Review article: test and treat or treat and test in reflux disease?
The role of diagnostic testing in reflux disease is in evolution. There is little question that patients with dysphagia, bleeding or other 'alarm' symptoms, should undergo early endoscopy. A substantial proportion of patients presenting with reflux symptoms have endoscopy negative reflux disease. pH testing is both inconvenient and lacks the sensitivity and specificity required for a 'gold standard'. Empirical trials of therapy using proton pump inhibitors have shown that a trial of treatment may be the most accurate way of diagnosing gastro-oesophageal reflux disease (GERD) and may the optimal strategy from a cost-effectiveness standpoint. On the other hand, the increasing rate of oesophageal adenocarcinoma has raised questions about the possible value of screening endoscopy to determine if Barrett's oesophagus is present. The role of endoscopic testing in the average patient is therefore shifting from a diagnostic modality to one that helps manage risk by identifying Barrett's oesophagus.
Vakil
N
N
Division of Gastroenterology, University of Wisconsin Medical School, Milwaukee, Wisconsin 53233, USA. nvakil@wisc.edu
D000230:Adenocarcinoma / Q000175:diagnosis / Q000628:therapy; D000553:Ambulatory Care; D000897:Anti-Ulcer Agents; D001471:Barrett Esophagus / Q000175:diagnosis / Q000628:therapy; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000628:therapy; D005764:Gastroesophageal Reflux / Q000175:diagnosis* / Q000628:therapy; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009853:Omeprazole
D000897:Anti-Ulcer Agents; D009853:Omeprazole